Csonka D - Search Results

1

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.

Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britten CD, Le N, Carter K, Demanse D, Csonka D, Peters M, Zubel A, Nauwelaerts H, Sessa C. Bedard PL, et al. Among authors: csonka d. Clin Cancer Res. 2015 Feb 15;21(4):730-8. doi: 10.1158/1078-0432.CCR-14-1814. Epub 2014 Dec 10. Clin Cancer Res. 2015. PMID: 25500057 Clinical Trial.

2

A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.

Csonka D, Hazell K, Waldron E, Lorenzo S, Duval V, Trandafir L, Kobalava ZD. Csonka D, et al. J Clin Pharmacol. 2016 Mar;56(3):316-23. doi: 10.1002/jcph.590. Epub 2015 Sep 14. J Clin Pharmacol. 2016. PMID: 26183800 Free PMC article. Clinical Trial.

3

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K. Massard C, et al. Among authors: csonka d. Eur J Cancer. 2017 May;76:36-44. doi: 10.1016/j.ejca.2017.01.024. Epub 2017 Mar 20. Eur J Cancer. 2017. PMID: 28282611 Clinical Trial.

4

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K. Massard C, et al. Among authors: csonka d. Eur J Cancer. 2017 Aug;81:242. doi: 10.1016/j.ejca.2017.05.003. Epub 2017 Jun 10. Eur J Cancer. 2017. PMID: 28606464 No abstract available.

5

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Grill S, Bruderer S, Sidharta PN, Antonova M, Globig S, Carlson J, Schultz A, Csonka D. Grill S, et al. Among authors: csonka d. Br J Clin Pharmacol. 2020 Dec;86(12):2424-2434. doi: 10.1111/bcp.14347. Epub 2020 May 29. Br J Clin Pharmacol. 2020. PMID: 32374030 Free PMC article.

6

Relative bioavailability of a pediatric dispersible tablet and adult film-coated tablet of macitentan in healthy volunteers.

Sidharta PN, Štěpánová R, Globig S, Ulč I, Csonka D. Sidharta PN, et al. Among authors: csonka d. Pharmacol Res Perspect. 2020 Apr;8(2):e00580. doi: 10.1002/prp2.580. Pharmacol Res Perspect. 2020. PMID: 32302056 Free PMC article. Clinical Trial.

7

Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic.

Csonka D, Fishman V, Natarajan J, Stieltjes H, Armas D, Dishy V, Perez Ruixo JJ. Csonka D, et al. Pharmacol Res Perspect. 2021 Oct;9(5):e00846. doi: 10.1002/prp2.846. Pharmacol Res Perspect. 2021. PMID: 34624174 Free PMC article. Clinical Trial.

8

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects.

Csonka D, Bruderer S, Schultz A, Soergel M, Stepanova R, Sabattini G, Perez-Ruixo JJ. Csonka D, et al. Clin Drug Investig. 2019 Dec;39(12):1223-1232. doi: 10.1007/s40261-019-00857-7. Clin Drug Investig. 2019. PMID: 31552642 Free PMC article.

9

A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.

Bartolucci R, Dosne AG, Csonka D, Pérez-Ruixo JJ, Magni P, Poggesi I. Bartolucci R, et al. Among authors: csonka d. Clin Pharmacokinet. 2021 Dec;60(12):1605-1619. doi: 10.1007/s40262-021-01049-3. Epub 2021 Jun 23. Clin Pharmacokinet. 2021. PMID: 34159557

10

Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.

Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin N, Savale L, Krowka M. Sitbon O, et al. Among authors: csonka d. Lancet Respir Med. 2019 Jul;7(7):594-604. doi: 10.1016/S2213-2600(19)30091-8. Epub 2019 Jun 6. Lancet Respir Med. 2019. PMID: 31178422 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters